HealthQuill China
Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. in a $2 billion deal.
Drugs Health Pharma

Merck signs $2b licensing deal with Jiangsu Hengrui for heart disease drug

HQ Team March 25, 2025: Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from.

Read More
Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and commercialising of the Chinese company’s “triple G” weight-loss candidate.
Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

Read More
Remember that Covid-19 is still with us, continuously evolving and forming new lineages and we still need to stay ahead of it. Maintaining a cautious vigilance rather than undue panic is the need of the day.
Health Research

Covid-like virus HKU5 discovered by China’s Wuhan Institute scientists

HQ Team February 24, 2025: Chinese virologists at the Wuhan Institute of Virology have found another bat coronavirus that carries the risk of.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US government’s accusations against the global health agency after the nation withdrew from being a member.
Drugs Health Medical

WHO director-general rebuts US criticism, plans to cut budget

Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US government’s accusations against the global.

Read More
China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic blood disorder.
Drugs Health Medical

China’s YolTech starts gene editing trial for treating a blood disorder 

China’s YolTech Therapeutics, a biotechnology startup, has started its clinical trial of an investigational therapy for treating transfusion-dependent beta-thalassemia (TDT), a severe genetic.

Read More
The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.
Climate Health Medical

US to pull out from Paris Agreement that limits global warming 

The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.

Read More
The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19 pandemic.
Health Medical Pharma

US to withdraw from WHO after an executive order from Donald Trump

The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19.

Read More
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More
China has approved Merck & Co.’s human papillomavirus vaccine for males between nine and 26 years amid a fall in sales for the jab among women in the world’s most populous country, according to a company statement.
Drugs Health Medical

China approves Merck’s human papillomavirus jab for use in males 

China has approved Merck & Co.’s human papillomavirus vaccine for males between nine and 26 years amid a fall in sales for the.

Read More